Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, C Vance, D Herich-Terhürne… - Annals of …, 2017 - Springer
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, C Vance… - Annals of …, 2017 - pubmed.ncbi.nlm.nih.gov
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, C Vance, D Herich-terhürne… - Annals of …, 2017 - search.proquest.com
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, C Vance, D Herich-Terhürne… - Annals of …, 2017 - europepmc.org
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, C Vance, D Herich-Terhürne, N Preising… - 2017 - cabidigitallibrary.org
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, D Herich-Terhürne, N Preising… - Annals of …, 2017 - elibrary.ru
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement …
F Alashkar, C Vance, D Herich-Terhürne… - Annals of …, 2017 - infona.pl
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …